The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D? David G. T. WhitehurstJohn E. BrazierBrendan J. Mulhern Commentary 10 September 2020 Pages: 1283 - 1288
Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer? Luke B. ConnellyStephen Birch Leading Article 08 September 2020 Pages: 1289 - 1295
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies Aris AngelisHuseyin NaciAllan Hackshaw Practical Application 22 September 2020 Pages: 1297 - 1308
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal Caroline FarmerAsh BullementLouise Crathorne Review Article 02 September 2020 Pages: 1309 - 1318
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach Jessica OchalekHaiyin WangChunlin Jin Original Research Article 28 August 2020 Pages: 1319 - 1331
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles Ching-Yu WangPhuong N. PhamJoshua D. Brown Original Research Article 14 September 2020 Pages: 1333 - 1343
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China Lei TianXiaomo XiongAixia Ma Original Research Article 15 September 2020 Pages: 1345 - 1358
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups Shweta MitalHai V. Nguyen Original Research Article 22 September 2020 Pages: 1359 - 1372
Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” Richard Manning Letter to the Editor 09 November 2020 Pages: 1373 - 1374
Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” William V. PadulaSonal ParasrampuriaGerard F. Anderson Letter to the Editor 09 November 2020 Pages: 1375 - 1376
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018 David D. KimMadison C. SilverPeter J. Neumann Correction Open access 21 October 2020 Pages: 1377 - 1377